Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections. Psoriasis is a chronic T-cell–mediated autoimmune diseas...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2012-03, Vol.366 (13), p.1181-1189 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1189 |
|---|---|
| container_issue | 13 |
| container_start_page | 1181 |
| container_title | The New England journal of medicine |
| container_volume | 366 |
| creator | Papp, Kim A Leonardi, Craig Menter, Alan Ortonne, Jean-Paul Krueger, James G Kricorian, Gregory Aras, Girish Li, Juan Russell, Chris B Thompson, Elizabeth H.Z Baumgartner, Scott |
| description | In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections.
Psoriasis is a chronic T-cell–mediated autoimmune disease
1
that affects 2 to 3% of the U.S. population
2
,
3
and 0.6 to 6.5% of the European population.
4
Emerging data identify a subset of helper T cells, Th17, that preferentially produce interleukin-17 and play a major role in orchestrating inflammation in psoriasis.
5
–
7
Levels of interleukin-17 are elevated in the lesional skin and blood of patients with psoriasis
5
,
8
–
10
and correlate with disease severity.
11
The interleukin-17 cytokine family consists of six cytokines (interleukins 17A to 17F) and five receptors (interleukins 17RA to 17RE).
12
The interleukin 17A, 17F, and 17A/F heterodimer ligands share . . . |
| doi_str_mv | 10.1056/NEJMoa1109017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_963488448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622150181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-dcc22511b41d2c4c9de97882e2f33377c7fd0a83357ec0ae61aa33e52316fdbb3</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgitbq0q0UQdw4mntmllVardQLoushk2Rg6kxSk5mFO9_BN_RJjLZewWwOOXycc_gB2EHwCEHGj69GF5dOIgQziMQK6CFGSEIp5KugByFOEyoysgE2Q5jB-BDN1sEGxpQxinAPjE-807LuGlkcDqQdDG1bvT6_TGxrfG26h8omSMTGrVFm3jr_AQqnnwZl_NwE5ysZqrAF1kpZB7O9rH1wPx7dnZ4n0-uzyelwmijKcZtopTBmCBUUaayoyrTJRJpig0tCiBBKlBrKlBAmjILScCQlIYZhgnipi4L0wcFi7ty7x86ENm-qoExdS2tcF_KME5qmlKZR7v2RM9d5G4-LCFNKMOERJQukvAvBmzKf-6qR_ilHMH-PN_8Vb_S7y6Fd0Rj9pT_zjGB_CWRQsi69tKoK345xStLsh2uakFsza_5Z-Aan444R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>962443236</pqid></control><display><type>article</type><title>Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Papp, Kim A ; Leonardi, Craig ; Menter, Alan ; Ortonne, Jean-Paul ; Krueger, James G ; Kricorian, Gregory ; Aras, Girish ; Li, Juan ; Russell, Chris B ; Thompson, Elizabeth H.Z ; Baumgartner, Scott</creator><creatorcontrib>Papp, Kim A ; Leonardi, Craig ; Menter, Alan ; Ortonne, Jean-Paul ; Krueger, James G ; Kricorian, Gregory ; Aras, Girish ; Li, Juan ; Russell, Chris B ; Thompson, Elizabeth H.Z ; Baumgartner, Scott</creatorcontrib><description>In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections.
Psoriasis is a chronic T-cell–mediated autoimmune disease
1
that affects 2 to 3% of the U.S. population
2
,
3
and 0.6 to 6.5% of the European population.
4
Emerging data identify a subset of helper T cells, Th17, that preferentially produce interleukin-17 and play a major role in orchestrating inflammation in psoriasis.
5
–
7
Levels of interleukin-17 are elevated in the lesional skin and blood of patients with psoriasis
5
,
8
–
10
and correlate with disease severity.
11
The interleukin-17 cytokine family consists of six cytokines (interleukins 17A to 17F) and five receptors (interleukins 17RA to 17RE).
12
The interleukin 17A, 17F, and 17A/F heterodimer ligands share . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1109017</identifier><identifier>PMID: 22455412</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Adult ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Cytokines ; Dermatology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug dosages ; Drug therapy ; Erythema ; Female ; General aspects ; Humans ; Immunotherapy ; Injections, Subcutaneous ; Interleukin 17 ; Light therapy ; Male ; Medical sciences ; Middle Aged ; Monoclonal antibodies ; Neutropenia ; Patients ; Psoriasis ; Psoriasis - drug therapy ; Psoriasis. Parapsoriasis. Lichen ; Receptors, Interleukin-17 - antagonists & inhibitors ; Receptors, Interleukin-17 - immunology ; Respiratory tract diseases ; Rhinopharyngitis ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>The New England journal of medicine, 2012-03, Vol.366 (13), p.1181-1189</ispartof><rights>Copyright © 2012 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-dcc22511b41d2c4c9de97882e2f33377c7fd0a83357ec0ae61aa33e52316fdbb3</citedby><cites>FETCH-LOGICAL-c462t-dcc22511b41d2c4c9de97882e2f33377c7fd0a83357ec0ae61aa33e52316fdbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1109017$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/962443236?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25643892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22455412$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papp, Kim A</creatorcontrib><creatorcontrib>Leonardi, Craig</creatorcontrib><creatorcontrib>Menter, Alan</creatorcontrib><creatorcontrib>Ortonne, Jean-Paul</creatorcontrib><creatorcontrib>Krueger, James G</creatorcontrib><creatorcontrib>Kricorian, Gregory</creatorcontrib><creatorcontrib>Aras, Girish</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><creatorcontrib>Russell, Chris B</creatorcontrib><creatorcontrib>Thompson, Elizabeth H.Z</creatorcontrib><creatorcontrib>Baumgartner, Scott</creatorcontrib><title>Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections.
Psoriasis is a chronic T-cell–mediated autoimmune disease
1
that affects 2 to 3% of the U.S. population
2
,
3
and 0.6 to 6.5% of the European population.
4
Emerging data identify a subset of helper T cells, Th17, that preferentially produce interleukin-17 and play a major role in orchestrating inflammation in psoriasis.
5
–
7
Levels of interleukin-17 are elevated in the lesional skin and blood of patients with psoriasis
5
,
8
–
10
and correlate with disease severity.
11
The interleukin-17 cytokine family consists of six cytokines (interleukins 17A to 17F) and five receptors (interleukins 17RA to 17RE).
12
The interleukin 17A, 17F, and 17A/F heterodimer ligands share . . .</description><subject>Adult</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cytokines</subject><subject>Dermatology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Erythema</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin 17</subject><subject>Light therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Receptors, Interleukin-17 - antagonists & inhibitors</subject><subject>Receptors, Interleukin-17 - immunology</subject><subject>Respiratory tract diseases</subject><subject>Rhinopharyngitis</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10MtKAzEUBuAgitbq0q0UQdw4mntmllVardQLoushk2Rg6kxSk5mFO9_BN_RJjLZewWwOOXycc_gB2EHwCEHGj69GF5dOIgQziMQK6CFGSEIp5KugByFOEyoysgE2Q5jB-BDN1sEGxpQxinAPjE-807LuGlkcDqQdDG1bvT6_TGxrfG26h8omSMTGrVFm3jr_AQqnnwZl_NwE5ysZqrAF1kpZB7O9rH1wPx7dnZ4n0-uzyelwmijKcZtopTBmCBUUaayoyrTJRJpig0tCiBBKlBrKlBAmjILScCQlIYZhgnipi4L0wcFi7ty7x86ENm-qoExdS2tcF_KME5qmlKZR7v2RM9d5G4-LCFNKMOERJQukvAvBmzKf-6qR_ilHMH-PN_8Vb_S7y6Fd0Rj9pT_zjGB_CWRQsi69tKoK345xStLsh2uakFsza_5Z-Aan444R</recordid><startdate>20120329</startdate><enddate>20120329</enddate><creator>Papp, Kim A</creator><creator>Leonardi, Craig</creator><creator>Menter, Alan</creator><creator>Ortonne, Jean-Paul</creator><creator>Krueger, James G</creator><creator>Kricorian, Gregory</creator><creator>Aras, Girish</creator><creator>Li, Juan</creator><creator>Russell, Chris B</creator><creator>Thompson, Elizabeth H.Z</creator><creator>Baumgartner, Scott</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120329</creationdate><title>Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis</title><author>Papp, Kim A ; Leonardi, Craig ; Menter, Alan ; Ortonne, Jean-Paul ; Krueger, James G ; Kricorian, Gregory ; Aras, Girish ; Li, Juan ; Russell, Chris B ; Thompson, Elizabeth H.Z ; Baumgartner, Scott</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-dcc22511b41d2c4c9de97882e2f33377c7fd0a83357ec0ae61aa33e52316fdbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cytokines</topic><topic>Dermatology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Erythema</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin 17</topic><topic>Light therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Receptors, Interleukin-17 - antagonists & inhibitors</topic><topic>Receptors, Interleukin-17 - immunology</topic><topic>Respiratory tract diseases</topic><topic>Rhinopharyngitis</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papp, Kim A</creatorcontrib><creatorcontrib>Leonardi, Craig</creatorcontrib><creatorcontrib>Menter, Alan</creatorcontrib><creatorcontrib>Ortonne, Jean-Paul</creatorcontrib><creatorcontrib>Krueger, James G</creatorcontrib><creatorcontrib>Kricorian, Gregory</creatorcontrib><creatorcontrib>Aras, Girish</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><creatorcontrib>Russell, Chris B</creatorcontrib><creatorcontrib>Thompson, Elizabeth H.Z</creatorcontrib><creatorcontrib>Baumgartner, Scott</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papp, Kim A</au><au>Leonardi, Craig</au><au>Menter, Alan</au><au>Ortonne, Jean-Paul</au><au>Krueger, James G</au><au>Kricorian, Gregory</au><au>Aras, Girish</au><au>Li, Juan</au><au>Russell, Chris B</au><au>Thompson, Elizabeth H.Z</au><au>Baumgartner, Scott</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2012-03-29</date><risdate>2012</risdate><volume>366</volume><issue>13</issue><spage>1181</spage><epage>1189</epage><pages>1181-1189</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections.
Psoriasis is a chronic T-cell–mediated autoimmune disease
1
that affects 2 to 3% of the U.S. population
2
,
3
and 0.6 to 6.5% of the European population.
4
Emerging data identify a subset of helper T cells, Th17, that preferentially produce interleukin-17 and play a major role in orchestrating inflammation in psoriasis.
5
–
7
Levels of interleukin-17 are elevated in the lesional skin and blood of patients with psoriasis
5
,
8
–
10
and correlate with disease severity.
11
The interleukin-17 cytokine family consists of six cytokines (interleukins 17A to 17F) and five receptors (interleukins 17RA to 17RE).
12
The interleukin 17A, 17F, and 17A/F heterodimer ligands share . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>22455412</pmid><doi>10.1056/NEJMoa1109017</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2012-03, Vol.366 (13), p.1181-1189 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_963488448 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Cytokines Dermatology Dose-Response Relationship, Drug Double-Blind Method Drug dosages Drug therapy Erythema Female General aspects Humans Immunotherapy Injections, Subcutaneous Interleukin 17 Light therapy Male Medical sciences Middle Aged Monoclonal antibodies Neutropenia Patients Psoriasis Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Receptors, Interleukin-17 - antagonists & inhibitors Receptors, Interleukin-17 - immunology Respiratory tract diseases Rhinopharyngitis Severity of Illness Index Treatment Outcome |
| title | Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A06%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brodalumab,%20an%20Anti%E2%80%93Interleukin-17%E2%80%93Receptor%20Antibody%20for%20Psoriasis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Papp,%20Kim%20A&rft.date=2012-03-29&rft.volume=366&rft.issue=13&rft.spage=1181&rft.epage=1189&rft.pages=1181-1189&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1109017&rft_dat=%3Cproquest_cross%3E2622150181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=962443236&rft_id=info:pmid/22455412&rfr_iscdi=true |